NXL insider filings
Nexalin Technology, Inc. — 46 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-17. Screen NXL transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Greenlight Ventures, LLC — 10% owner | 1 | — | — | — |
Recent insider filings — Nexalin Technology, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 3 | Greenlight Ventures, LLC — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2025-12-23 | 4 | White Mark — CEO, Director | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Van Fleet Justin — CFO | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Owens David — Chief Medical Officer, Director | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Shelton Carolyn Hamby — Sr. VP - Quality - Regulatory | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Hu Ben — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Kazden Alan — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | Owens David — Chief Medical Officer, Director | Grant/award (A): 36,459 @ $0 | EDGAR |
| 2025-09-30 | 4 | Hu Ben — Director | Grant/award (A): 36,459 @ $0 | EDGAR |
| 2025-09-30 | 4 | Kazden Alan — Director | Grant/award (A): 36,459 @ $0 | EDGAR |
| 2025-09-30 | 4 | OSSER LEONARD — 10% owner Elson Marilyn | Grant/award (A): 83,333 @ $0 | EDGAR |
| 2025-09-12 | 4 | Shelton Carolyn Hamby — Sr. VP - Quality - Regulatory | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Owens David — Chief Medical Officer, Director | Grant/award (A): 203,125 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Elson Marilyn — 10% owner OSSER LEONARD — 10% owner | Sale (S): 23,150 (derivative) @ $0.02 | EDGAR |
| 2025-07-21 | 4 | Elson Marilyn — 10% owner OSSER LEONARD | Grant/award (A): 150,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | Shelton Carolyn Hamby — Sr. VP - Quality, Regulatory | Purchase (P): 6,000 @ $2.20 | EDGAR |
| 2025-02-27 | 4 | White Mark — President and CEO, Director | Grant/award (A): 447,427 (derivative) @ $0 · Grant/award (A): 939,597 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Owens David — Chief Medical Officer, Director | Grant/award (A): 139,821 (derivative) @ $0 · Grant/award (A): 654,363 (derivative) @ $0 · Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Owens David — Chief Medical Officer, Director | Purchase (P): 1,000 @ $3.10 | EDGAR |
| 2025-02-04 | 4 | Owens David — Chief Medical Officer, Director | Purchase (P): 1,000 @ $2.98 | EDGAR |
| 2025-01-29 | 4 | Owens David — Chief Medical Officer, Director | Purchase (P): 1,500 @ $2.70 | EDGAR |
| 2025-01-24 | 4 | Owens David — Chief Medical Officer, Director | Purchase (P): 2,000 @ $2.50 · Purchase (P): 1,000 @ $2.70 | EDGAR |
| 2024-10-30 | 4 | Owens David — Chief Medical Officer, Director | Purchase (P): 500 @ $2.19 | EDGAR |
| 2024-10-02 | 4 | Hu Ben — Director | Grant/award (A): 175,000 @ $0 | EDGAR |
| 2024-10-02 | 4 | Bernhard Leslie — Director | Grant/award (A): 49,838 @ $0 | EDGAR |
| 2024-10-02 | 4/A | Elson Marilyn — 10% owner OSSER LEONARD | Grant/award (A): 700,000 @ $0 | EDGAR |
| 2024-09-25 | 4 | Elson Marilyn — 10% owner OSSER LEONARD | Grant/award (A): 700,000 @ $0 | EDGAR |
| 2024-09-25 | 4/A | Elson Marilyn — 10% owner OSSER LEONARD | Purchase (P): 36,000 (derivative) @ $0.40 | EDGAR |
| 2024-08-15 | 4 | Owens David — Chief Medical Officer, Director | Purchase (P): 1,000 @ $0.95 | EDGAR |
| 2024-07-01 | 4 | Owens David — Chief Medical Officer, Director | Purchase (P): 1,000 @ $1.75 | EDGAR |
| 2024-06-21 | 4 | Owens David — Chief Medical Officer, Director | Purchase (P): 1,619 @ $0.71 | EDGAR |
| 2024-06-12 | 4 | Owens David — Chief Medical Officer, Director | Purchase (P): 2,000 @ $0.65 · Purchase (P): 1,000 @ $0.62 | EDGAR |
| 2023-10-05 | 4 | White Mark — President/CEO, Director | Purchase (P): 25,000 (derivative) @ $0.40 | EDGAR |
| 2023-10-05 | 4 | Owens David — Chief Medical Officer, Director | Purchase (P): 2,500 (derivative) @ $0.40 | EDGAR |
| 2023-10-05 | 4 | Kazden Alan — Director | Purchase (P): 2,500 (derivative) @ $0.40 | EDGAR |
| 2023-10-05 | 4 | Elson Marilyn — Ms. Elson serves as CFO, 10% owner OSSER LEONARD | Purchase (P): 9,500 (derivative) @ $0.40 | EDGAR |
| 2023-06-30 | 4/A | Morad Rick — Director | Purchase (P): 2,500 @ $4.15 | EDGAR |
| 2023-06-30 | 4/A | White Mark — President/CEO, Director | Purchase (P): 25,000 @ $4.15 | EDGAR |
| 2023-06-30 | 4/A | Kazden Alan — Director | Purchase (P): 2,500 @ $4.15 | EDGAR |
| 2022-09-29 | 4 | Elson Marilyn — Ms. Elson serves as CFO, 10% owner OSSER LEONARD | Purchase (P): 9,500 @ $1.12 | EDGAR |
| 2022-09-22 | 4/A | White Mark — President/CEO, Director | Purchase (P): 25,000 @ $4.15 | EDGAR |
| 2022-09-20 | 4 | Morad Rick — Director | Purchase (P): 2,500 @ $4.15 | EDGAR |
| 2022-09-20 | 4 | Kazden Alan — Director | Purchase (P): 2,500 @ $4.15 | EDGAR |
| 2022-09-20 | 4 | Owens David — Chief Medical Officer, Director | Purchase (P): 2,500 @ $4.15 | EDGAR |
| 2022-09-20 | 4 | White Mark — President/CEO, Director | Purchase (P): 2,500 @ $4.15 | EDGAR |
| 2022-09-20 | 4 | Elson Marilyn — Ms. Elson serves as CFO, 10% owner OSSER LEONARD | Purchase (P): 36,000 @ $4.15 · Purchase (P): 100,000 (derivative) @ $0.40 | EDGAR |
Recent 8-K events — Nexalin Technology, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-01 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-10-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-28 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-09-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-27 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-17 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-07-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
Registration filings — Nexalin Technology, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-298744 (S-1) — latest: Amendment (S-1/A), filed 2026-10-08
GET https://api.filingpulse.io/v1/insider-trades?ticker=NXL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs